Leerink Swann upgrades Acorda Therapeutics (Nasdaq: ACOR) from Underperform to Outperform and raises their price target from $15 to $30 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE